IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas

Authors: G. Sari, K. Dhatchinamoorthy, L. Orellano-Ariza, L. M. Ferreira, M. A. Brehm, K. Rock

Published: 2024-10-02

DOI: 10.1186/s13046-024-03187-5

Source: Full article